A study analyzing role of histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response
Latest Information Update: 20 Jul 2022
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Pharmacodynamics; Therapeutic Use
- 01 Aug 2022 Results published in the Melanoma Research
- 20 Jul 2022 New trial record